Foghorn Therapeutics Inc. (FHTX) Balance Sheet

The deficit peaked near negative $14.3M in 2024Q2 and then widened sharply, so the recent improvement is a partial recovery rather than a sustained repair. Total assets have contracted about 38% from their 2024Q2 peak of $328.6M, which suggests cash consumption is shrinking the asset base faster than liabilities are being retired. Investors should monitor whether the deficit continues to narrow through revenue recognition or equity events rather than asset erosion.

Because equity is negative, the D/E ratio shown as not applicable does not convey leverage intensity, and the more relevant signal is that debt has been roughly stable between $22.5M and $43.1M over the period. The debt balance has risen since 2025Q3, which may indicate new borrowing to fund operations, though the filing data alone does not reveal terms or maturities. Refinancing risk cannot be assessed without maturity schedules, so this warrants further investigation.

The current ratio has fluctuated between 2.16 and 5.69, with the most recent reading reflecting a shrinking cash balance rather than a strengthening position. With operating cash burn persistently exceeding net losses, the cash runway implied by current holdings appears finite and investors should monitor the pace of cash depletion closely. Liquidity conclusions depend on near-term financing access, which the supplied data does not disclose.

The accumulated deficit increases every quarter, consistent with the persistent operating losses reported in the income statement, which indicates equity is being eroded by research spending rather than by one-time charges. Share repurchases of $49.8M in 2026Q2 further reduce equity while cash burn continues, which appears to deepen the deficit at the margin. The combined effect suggests capital allocation toward buybacks is being funded despite negative free cash flow, a pattern that warrants scrutiny.

Deferred revenue held near $245M to $280M through 2025 before the sharp reduction, which suggests a large upfront arrangement was largely recognized in the most recent periods. The 2026Q2 revenue spike is consistent with this recognition, meaning forward revenue visibility is weaker than the headline quarter implies. Investors should monitor whether new deferred balances replenish, since the current figure offers limited support for future revenue durability.